January 19, 2017 6:22 AM ET

Life Sciences Tools and Services

Company Overview of Pacific Biosciences of California, Inc.

Company Overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company’s single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including sealed and packaged SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits to run the PacBio RS II or Sequel System. Its customers include research institutions; commercial laboratories; genome centers; cli...

1380 Willow Road

Menlo Park, CA 94025

United States

Founded in 2000

394 Employees



Key Executives for Pacific Biosciences of California, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 67
Total Annual Compensation: $1.0
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Age: 62
Total Annual Compensation: $1.0
Senior Vice President of Research and Development
Age: 65
Total Annual Compensation: $424.3K
Senior Vice President of Market Development
Age: 57
Total Annual Compensation: $424.3K
Compensation as of Fiscal Year 2015.

Pacific Biosciences of California, Inc. Key Developments

Pacific Biosciences Improves Key Applications on the Sequel System with New Chemistry and Software Release

Pacific Biosciences of California, Inc. announced a new version of chemistry (V2) and software (V4) for the Sequel™ System. The new release improves the system’s ability to support important applications such as structural variant detection and targeted sequencing— including metagenomics, minor variant detection and isoform sequencing— by achieving mean read lengths of 10-15 kb, with half of the data in reads > 20 kb, and throughput from 5-8 Gb. In addition to these applications, the high consensus accuracy, uniform coverage, and long read lengths inherent to the Sequel System continue to make it ideal for applications such as de novo genome assembly. The Sequel System is PacBio’s latest platform based on its Single Molecule, Real-Time (SMRT®) Sequencing technology. Since the launch of the system in fall of 2015, PacBio has installed more than 110 Sequel Systems globally. The latest release includes a new version of the consumable SMRT Cells that is tuned for the new sequencing chemistry kits. The company has also made updates to its base calling algorithm that increase accuracy, and added new features in the Sequel System software package designed for clinical research applications. The V2 chemistry and V4 software updates will be available on January 23, 2017. This release improves users’ ability to perform low-fold structural variant detection and key targeted sequencing applications. For structural variant detection, they can now accomplish the same or better quality of results for structural variant analysis using, on average, half the number of SMRT Cells compared to the previously available chemistry. Long read lengths provided by the new chemistry also enable the detection of larger-scale structural variants, in particular there is a 3-fold increase in sensitivity of insertions over 5 kb. For targeted sequencing, the new chemistry and the software gives users more flexibility.

Pacific Biosciences of California, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 03:30 PM

Pacific Biosciences of California, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 03:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Michael W. Hunkapiller, Executive Chairman, Chief Executive Officer and President.

Roche Announces Termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences

Roche announced that it has officially notified Pacific Bioscience of its intention to terminate its agreement and efforts to develop a sequencing instrument for use in the clinical research and clinical market using their Single Molecule, Real-Time (SMRT®) technology. With this termination, Roche no longer retains rights to this technology and PacBio is free to approach any market segments with their SMRT technology.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

January 16, 2017
Pacific Biosciences of California, Inc., 10 Sequel Systems, so-Seq annotation

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Pacific Biosciences of California, Inc., please visit www.pacb.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.